Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

"Prehistoric relics" as targets for vaccination against cancer

02.09.2013
Researchers at the Paul-Ehrlich-Institut have succeeded in using a peculiarity of cancer cells for targeted immunological attack: While endogenous retroviruses are inactive in healthy cells, cancer cells produce proteins of these viruses.

With a vaccine directed against endogenous retroviruses, the progression of tumour growth could be significantly inhibited in a mouse model. The prophylactic vaccination could even prevent the development of tumours. The results of this research project were reported in the online edition of PLoS ONE dated 30 August 2013 (11 p.m. CET).


The murine renal carcinoma cell line Renca. On the left: without HERV-K envelope protein expression. On the right: genetically modified Renca cells with HERV-K envelope protein (in red).


Source: PEI - The image is available with 300 dpi (4,7x13,7 cm) - please ask the PEI Press and information office

Human endogenous retroviruses (HERV) entered the human genome millions of years ago and have been passed on from generation to generation. The human genome contains several thousand such endogenous retrovirus genes. As a rule, the genes of HERV are mute, i.e. they do not produce proteins. Researchers of the Paul-Ehrlich-Institut and other groups have already been able to show that an increase in expression of genes of one group of these retroviruses occurs in HIV infected individuals but also in the tumour cells of various types of cancer. The HERV group could be identified as HERV-K/HML-2(hom), or for short, HERV-K. Professor Dr Barbara Schnierle and her co-workers in the Virology Division of the Paul-Ehrlich-Institut now wanted to know whether the specific gene activity of HERV-K could be used therapeutically to fight cancer cells in a targeted manner. To protect healthy cells, it is required to identify structures as targets which are only displayed on cancer cells.

For their investigations, Professor Barbara Schnierle, head of the Section "AIDS, New and Emerging Pathogens", and her co-workers used a murine kidney cell line (Renca). This cell line had been genetically modified in such a way that the cells produced (human) HERV-K envelope proteins to emulate the situation of the HERV-positive human cancer cells as accurately as possible. Mice which received an i.v. administration of these cells developed lung metastases within a short period of time.

For the "vaccination" against these tumours, the researchers used the modified vaccinia virus Ankara (MVA), an attenuated virus which cannot replicate after inoculation. In addition, Professor Schnierle and her co-workers had inserted the gene for the HERV-K envelope protein into the MVA genome. After the inoculation, the gene is read in the cells and the envelope protein is formed. It is presented to the immune system as antigen and an immune response can be induced.

Then the PEI scientists performed investigations to establish whether their "vaccine" could be used both for therapeutic and for prophylactic purposes: For the therapeutic approach, they first injected the genetically modified mouse cancer cells, then waited ten days until lung metastases were formed and then treated part of the mice with the MVA vaccine. The tumours grew considerably more slowly in the vaccinated animals and fewer metastases were observed than in the non-vaccinated animals. However, complete tumour remission was not achieved.

With regard to the prophylactic vaccination, the effect was even more significant: Here, the animals were at first vaccinated twice with the virus (days 0 and 21), and the cancer cells were administered twelve days later. The animals thus vaccinated were protected entirely from tumour development – no metastases could be identified.

"The findings have shown for the first time that the HERV-K envelope protein could be a useful target for the development of a vaccine, and may be able to provide new options for the treatment of various tumours" explained Professor Schnierle.

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen in the federal state of Hessen, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072756 Publication (Fulltext)

http://www.pei.de/EN/information/journalists-press/press-releases/2013/04-prehistoric-relics-targets-vaccination-against-cancer.html

Press Release on the PEI-Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de

More articles from Life Sciences:

nachricht Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex

nachricht New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>